| Identification | Back Directory | [Name]
BID | [CAS]
1416258-16-6 | [Synonyms]
BID
FP497
p22 BID
MGC15319
MGC42355
((plusmn))-BI-D
BID from mouse
BID, GST tagged human
BH3-interacting domain death agonist
ANTI-MOUSE BID (S61) antibody produced in rabbit
Recombinant Human BID/BH3-interacting domain death agonist protein Protein, No Tag
3-Quinolineacetic acid, 4-(3,4-dihydro-2H-1-benzopyran-6-yl)-α-(1,1-dimethylethoxy)-2-methyl- | [Molecular Formula]
C25H27NO4 | [MDL Number]
MFCD03456213 | [MOL File]
1416258-16-6.mol | [Molecular Weight]
405.49 |
| Chemical Properties | Back Directory | [Boiling point ]
587.3±50.0 °C(Predicted) | [density ]
1.203±0.06 g/cm3(Predicted) | [storage temp. ]
−20°C
| [solubility ]
DMSO: ≥ 100 mg/mL (246.62 mM) | [form ]
buffered aqueous solution
| [pka]
1.38±0.30(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
(±)-BI-D is a potent ALLINI(An allosteric IN inhibitor) that binds integrase at the LEDGF/p75 binding site.
IC50 value: 2.4–2.9 μM(HIV-Luc infection of WT and Hdgfrp2 KO cells) [1]
Target: integrase inhibitor
in vitro: Approximately 2.4–2.9 μM of BI-D was required to inhibit 50% of HIV-Luc infection of WT and Hdgfrp2 KO cells, while the IC50 decreased dramatically, to 160–200 nM, in Psip1 and double-KO cells [1]. | [References]
[1] Wang H, et al. HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res. 2012 Dec;40(22):11518-30. DOI:10.1093/nar/gks913
[2] Fader LD, et al. Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV. ACS Med Chem Lett. 2014 Apr 16;5(6):711-6. DOI:10.1021/ml500110j |
|
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
|